Persistent Impairment of T-Cell Regeneration in a Patient with Activated PI3K δ Syndrome

J Clin Immunol. 2017 May;37(4):347-350. doi: 10.1007/s10875-017-0393-7. Epub 2017 Apr 21.

Authors

Fumihiro Goto¹, Toru Uchiyama², Yumiko Nakazawa¹, Kohsuke Imai³, Toshinao Kawai¹, Masafumi Onodera¹

Affiliations

¹ Department of Human Genetics, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan.
² Department of Human Genetics, National Center for Child Health and Development, 2-10-1 Okura, Setagaya-ku, Tokyo, 157-8535, Japan. uchiyama-t@ncchd.go.jp.
³ Department of Community Pediatrics, Perinatal and Maternal Medicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-Ku, Tokyo, 113-8510, Japan.

PMID: 28432485
DOI: 10.1007/s10875-017-0393-7

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Child, Preschool
Class I Phosphatidylinositol 3-Kinases / immunology
Humans
Immunologic Deficiency Syndromes / diagnostic imaging
Immunologic Deficiency Syndromes / drug therapy*
Immunologic Deficiency Syndromes / immunology*
Immunosuppressive Agents / therapeutic use*
Male
Prednisolone / therapeutic use*
Primary Immunodeficiency Diseases
Rituximab / therapeutic use
Sirolimus / therapeutic use*
T-Lymphocytes / immunology*

Substances

Immunosuppressive Agents
Rituximab
Prednisolone
Class I Phosphatidylinositol 3-Kinases
Sirolimus

Supplementary concepts

Activated PI3K-delta Syndrome